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and BACH2 genes correlates with the
composition of the immunoglobulin G
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Abstract
Background: Many genome- and epigenome-wide association studies (GWAS and EWAS) and studies of promoter
methylation of candidate genes for inflammatory bowel disease (IBD) have demonstrated significant
associations between genetic and epigenetic changes and IBD. Independent GWA studies have identified
genetic variants in the BACH2, IL6ST, LAMB1, IKZF1, and MGAT3 loci to be associated with both IBD and
immunoglobulin G (IgG) glycosylation.
Methods: Using bisulfite pyrosequencing, we analyzed CpG methylation in promoter regions of these five
genes from peripheral blood of several hundred IBD patients and healthy controls (HCs) from two independent cohorts,
respectively.
Results: We found significant differences in the methylation levels in the MGAT3 and BACH2 genes between both
Crohn’s disease and ulcerative colitis when compared to HC. The same pattern of methylation changes was identified
for both genes in CD19+ B cells isolated from the whole blood of a subset of the IBD patients. A correlation analysis was
performed between the MGAT3 and BACH2 promoter methylation and individual IgG glycans, measured in the same
individuals of the two large cohorts. MGAT3 promoter methylation correlated significantly with galactosylation, sialylation,
and bisecting GlcNAc on IgG of the same patients, suggesting that activity of the GnT-III enzyme, encoded by this gene,
might be altered in IBD. The correlations between the BACH2 promoter methylation and IgG glycans were less obvious,
since BACH2 is not a glycosyltransferase and therefore may affect IgG glycosylation only indirectly.
Conclusions: Our results suggest that epigenetic deregulation of key glycosylation genes might lead to an increase in
pro-inflammatory properties of IgG in IBD through a decrease in galactosylation and sialylation and an increase of
bisecting GlcNAc on digalactosylated glycan structures. Finally, we showed that CpG methylation in the promoter of the
MGAT3 gene is altered in CD3+ T cells isolated from inflamed mucosa of patients with ulcerative colitis from a third
smaller cohort, for which biopsies were available, suggesting a functional role of this glyco-gene in IBD pathogenesis.
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Background
Inflammatory bowel disease (IBD) is a chronic intestinal
inflammatory condition classified in two major forms—
Crohn’s disease (CD) and ulcerative colitis (UC)—which
exhibit etiologically and clinically distinct features. Now-
adays, IBD affects 2.5–3 million people in Europe and
causes considerable morbidity [1]. Despite numerous
clinical, genetic, and other experimental studies, our
understanding of IBD development and progression
remains incomplete.
It is generally accepted that IBD represents an aber-
rant immune response to gut microbiota in genetically
susceptible individuals [2]. Genome-wide association
studies (GWAS) have identified over 200 genetic suscep-
tibility loci, the majority of which were associated with
both forms of IBD in genome-wide meta-analysis [3–7].
However, common genetic variants account only for 8.2
and 13.1% heritability of UC and CD, respectively [7].
Interaction of an individual’s gut microbiome, im-
mune system, genetic background, and environmental
factors, such as smoking, diet, drugs, and physical
activity [2, 8–10], makes IBD a complex etiopatho-
genic entity. The challenge is therefore to identify
additional factors involved in the development and
progression of this disease, especially given its rapidly
increasing incidence. It is probable that epigenetics
play a key role in the interactions between environ-
mental, microbial, and genetic factors that participate
in IBD development and progression. These include
DNA methylation and histone modifications, as well
as some other epigenetic mechanisms [11–13]; for a
review, see [14, 15].
DNA methylation remains the most studied epigenetic
modification, readily assayed in a large number of indi-
viduals/samples. Hypermethylation of gene promoters is
generally associated with gene silencing, while promoter
hypomethylation is associated with gene activation [16].
Environmentally changed DNA methylation pattern may
contribute to the development of many complex diseases
by mediating the interplay between external and internal
factors and the gene expression [17–21]. There are also
data to suggest that the aforementioned environmen-
tal modifiers of IBD can also affect DNA methylation
[17–19, 22]. Epigenetic component of IBD has been
addressed in many studies, mostly by whole genome
methylation analysis performed on peripheral blood
mononuclear cells (PBMCs) or mucosal tissue, reveal-
ing regions differentially methylated between the
disease and healthy state, as well as between CD and
UC [11–13, 23–26].
The majority of eukaryotic proteins are modified by
addition of complex oligosaccharides (glycans) through
the process of glycosylation. Therefore, glycans are an
integral part of nearly all membrane and secreted
proteins, including components of the immune system
[27]. Aberrant protein glycosylation is implicated in
virtually every human complex disease, including inflam-
mation [28–31]. Previous studies have suggested that
N-glycosylation of secreted and membrane proteins
might be regulated epigenetically and that aberrant gly-
cosylation profiles in disease can arise through aberrant
epigenetics [32–38]. A comprehensive review about the
role of protein glycosylation in IBD has been given
recently [39]. N-glycosylation of serum-circulating pro-
teins (such as the acute phase proteins; immunoglobulin
G, IgG; and immunoglobulin A, IgA) or whole plasma
N-glycome (i.e., N-glycans present on all plasma pro-
teins) has been the focus of IBD biomarker discovery
[36, 40–43]. In addition, our partners from IBD consor-
tium and others established that altered glycosylation of
IgG, which is a key effector of the humoral immune
system, has a role in balancing inflammation at the sys-
temic level [42–46].
GWA studies indicated associations of IBD with sev-
eral loci involved in protein glycosylation [47, 48]. More
recently, the first GWAS of IgG glycosylation identified
16 loci specifically associated with changes in IgG glyco-
sylation [49]. Interestingly, five of these loci showed plei-
otropy with IBD: MGAT3, a glyco-gene encoding for a
glycosyltransferase, GnT-III; LAMB1, a member of
transmembrane glycoprotein family of extracellular
matrix; the IL6ST, a signal transducer shared by many
cytokines; IKZF1; and BACH2, transcription factors in-
volved in B cell differentiation, activation, and matur-
ation. Only the MGAT3 is a classical glyco-gene with a
known function in IgG glycosylation, while the exact
functional roles for other four GWAS hits in IgG glyco-
sylation or IBD remain unknown.
In this study, we investigated promoter methylation
differences in these five genes, associated with both IBD
and IgG glycosylation, in peripheral whole blood of
several hundred IBD patients from two independent
cohorts. We also correlated promoter methylation data
with IgG glycosylation data analyzed previously for the
same IBD patients by our partners from the IBD consor-
tium [43, 46, 50]. Peripheral blood was used for DNA
methylation analysis and serum or plasma was used for
glycan analysis, since one of our goals was the search for
potential IBD biomarkers. As peripheral whole blood is
a heterogeneous cell mixture with specific methylation
pattern for each of the cell types [51], we also analyzed
promoter methylation of our candidate genes in CD19+
B cells and CD3+ T cells isolated from peripheral blood
mononuclear cells (PBMCs). B cells were of our particu-
lar interest since these cells produce IgG on their mem-
brane and are precursors of plasma cells which secrete
IgG. We have further explored if aberrant promoter
methylation recorded in peripheral whole blood of IBD
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patients can be a proxy for epigenetic events occurring
in the inflamed mucosa. To address this question, we
analyzed DNA methylation from PBMCs, CD3+ T cells
isolated from PBMCs, and CD3+ T cells isolated from
inflamed colonic mucosa of UC patients from the third
smaller cohort, for which biopsies were available.
Methods
Patient selection and ethics
Patients were recruited prospectively from Edinburgh,
UK, and Florence, Italy, as a part of the IBD-BIOM pro-
ject. The recruitment of patients from Edinburgh has been
described elsewhere [13, 43]. Briefly, we recruited IBD
patients prospectively as close as possible to the date of
diagnosis from gastroenterology outpatient and endoscopy
appointments between 2012 and 2015. We recruited
symptomatic controls from gastroenterology clinics dur-
ing the same period. In these individuals, we had excluded
IBD and other organic bowel pathology following bio-
chemical and/or endoscopic investigations. We recruited
a further healthy volunteer cohort with no gastrointestinal
symptoms. IBD patients were stratified by disease type
(ulcerative colitis, UC, and Crohn’s disease, CD). Detailed
genetic, phenotypic, and other data regarding IBD cases
are given in Additional file 1: Tables S1 and S2. Florence
cohort was collected through the network of the Italian
Group for IBD (IG-IBD) since the beginning of 2001 and
first described in 2005 [1] following an internal validation
of phenotyping. Subsequently, longitudinal update has
been performed on a yearly basis.
Ethical approvals were obtained from Tayside Com-
mittee on Medical Ethics B, and all patients and controls
provided written, informed consent (LREC 06/S1101/16,
LREC 2000/4/192).
Florence recruitment details
IBD patients were prospectively recruited as close as
possible to the date of diagnosis from gastroenterology
outpatient and endoscopy appointments between years
2012 and 2015 in different tertiary referral centers in
San Giovanni Rotondo, Rome, Rozzano (Milan), Padua,
and Florence, Italy. Symptomatic controls were recruited
in the same centers (gastroenterology clinics) during the
same period. In these individuals, IBD and other organic
bowel pathology were excluded by biochemical and/or
endoscopic investigations. IBD patients were stratified
by disease type (ulcerative colitis, UC, and Crohn’s
disease, CD). Samples were obtained with the same
methodology (see further) and centrally collected at San
Giovanni Rotondo, Italy.
Sample collection
We collected whole blood at the time of patient recruit-
ment into 9-ml serum Z-clot activator tubes (Greiner),
allowed them to clot at 4 °C for 60 min, and then centri-
fuged at 2500×g for 15 min. The serum was aliquoted
off and stored at − 80 °C until further analysis.
A subset of patients and controls recruited in Edinburgh
(Additional file 1: Table S3) underwent immunomagnetic
cell separation to obtain CD19+ B cells. The methods have
previously been detailed elsewhere [13]. Venepuncture
using 9-ml K3 EDTA vacuette (Greiner) tubes was
performed to obtain between of 18 and 36 ml of
EDTA-buffered blood. An initial Ficoll (Ficoll-Paque, GE
Healthcare, Bucks, UK) density gradient centrifugation
was performed to obtain peripheral blood mononuclear
cells. Cells labelled with antibody-coated microbeads
(human CD8+ and CD19+ microbeads, 20 μl per 1 × 107
cells) were immunomagnetic separated using the auto-
MACs Pro cell separator (Miltenyi, Germany). CD19+
separations were performed following an initial CD8+
depletion step. Nucleic acids were extracted using AllPrep
(Qiagen, Hilden, Germany) according to the manufac-
turer’s guidance and stored at − 80 °C.
Colonic biopsies from controls and UC patients with
inactive and active form of disease were mechanically
dissociated to prepare single-cell suspensions using
Hanks’ balanced salt solution modified medium, without
calcium chloride and magnesium sulfate (HBSS) (Sigma),
with penicillin/streptomycin and gentamicin. PBMCs
were obtained by density gradient centrifugation using
Lymphoprep. CD3+ T cells (from biopsies and blood)
were magnetically sorted by using the EasySep™ Human
T Cell Enrichment Kit (STEMCELL) following the man-
ufacturer’s instructions. Following cell isolation, DNA
extraction was performed using the Invisorb Spin Tissue
Mini Kit (Stratec Molecular) following the manufac-
turer’s instructions.
DNA methylation analysis
We analyzed promoter methylation of the candidate
genes in the DNA from whole blood, as well as from the
separated CD19+ B cells. In addition, for the MGAT3,
which is a glycosyltransferase with direct and known
function in IgG glycosylation [52], we analyzed promoter
methylation—in DNA from PBMCs, CD3+ T cells iso-
lated from PBMCs, and CD3+ T cells isolated from the
colonic mucosa of healthy controls and UC patients
(classified according to active and inactive form of the
disease) of the third independent smaller subcohort col-
lected by the Gastroenterology Department of Centro
Hospitalar do Porto-Hospital de Santo António, Portugal
(Additional file 1: Table S4). All specimens were sub-
jected to histological examination and classification. All
participants gave informed consent about all clinical
procedures, and research protocols were approved by
the ethics committee of CHP/HSA, Portugal (233/
12(179-DEFI/177-CES).
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For DNA methylation analysis, 500 ng of DNA from
whole blood was bisulfite converted using EZ-96 DNA
Methylation Gold kit (Zymo Research, Freiburg,
Germany), and 100 ng of DNA from CD19+ B cells,
PBMCs, and T cells was converted using EZ DNA
Methylation Gold kit (Zymo Research, Freiburg,
Germany) according to the manufacturer’s protocol.
Two to six pyrosequencing assays were developed for
promoter regions of each of the five candidate genes
(BACH2, MGAT3, IL6ST, IKZF1, and LAMB1). The se-
lection of analyzed CpG sites was random for assays 2–5
of the MGAT3 gene. CpG sites within the MGAT3 assay
1 were selected based on the GEO (Gene Expression
Omnibus) database where methylation data were
obtained using Illumina HumanMethylation450 Bead-
Chip v1.1 technology. For the BACH2 gene, assays were
selected based on location of differentially methylated
CpGs in different cell lines tested by ENCODE project,
using Illumina HumanMethylation450 BeadChip v1.1
technology (a newer version, the Infinium MethylationE-
PIC 850K was not available at the time). We used
traditional bisulfite-based protocols which cannot
discriminate between 5-methylcytosine (5-mC) and
5-hydroxymethylcytosine (5-hmC) as oxidative bisulfite
(oxBS-450K) method can [53]. However, recent studies
have shown that global DNA hydroxymethylation is very
low in blood cells [54, 55]. Furthermore, hydroxymethy-
lation is significantly depleted from promotors and CpG
islands, while enriched in the gene bodies [53, 56].
Based on the estimated statistical power, we did initial
screening on 60 patients for each pyrosequencing assay,
after which we excluded those genes (pyrosequencing
assays) that did not show any statistically significant dif-
ferences between IBD patients and healthy controls.
Pyrosequencing assays for LAMB1, IL6ST, and IKZF1
are shown in Additional file 2: Figure S1. We continued
to analyze promoter methylation only in the BACH2 and
MGAT3 genes. Specific regions were amplified using
PyroMark PCR kit (Qiagen, Hilden, Germany). The cyc-
ling conditions for the BACH2 gene were as follows: ini-
tial polymerase activation step for 15 min at 95 °C
followed by 50 cycles of 30 s denaturation at 95 °C, pri-
mer annealing for 30 s at primer-specific temperatures
(Additional file 1: Table S5), and 30 s at 72 °C, with final
extension at 72 °C for 10 min. The cycling protocol used
for amplification of the MGAT3 gene fragments was de-
scribed previously [35], with the annealing temperature
adjusted to 55 °C for the fragment 1 performed on DNA
from CD19+ B cells. For quantitative measurement of
DNA methylation level at specific CpG sites,
PCR-amplified bisulfite-converted DNA was sequenced
using the PyroMark Q24 Advanced pyrosequencing sys-
tem (Qiagen) according to the manufacturer’s recom-
mendations. Sequences of PCR and pyrosequencing
primers for the BACH2 and the MGAT3 genes are listed
in Additional file 1: Table S5. EpiTect PCR Control DNA
Set (methylated and unmethylated bisulfite-converted
human DNA, Qiagen) was used as a control for PCR and
pyrosequencing reactions.
Statistical analysis
The nonparametric Mann-Whitney U test was used to
compare the methylation status of CpG sites encom-
passed by the pyrosequencing assays in the MGAT3 and
BACH2 genes between the two independent groups: HC
compared to each of CD or UC. Significance threshold
was set at p < 0.05 with additional Bonferroni correction
for multiple testing. Given that age was our primary
concern as a potential confounder, we visualized the age
in the three groups (CD, UC, and HC) for the samples
included in each analysis as violin plots (Additional file 3:
Figure S2) and assured there was no significant differ-
ence between the age groups (p > 0.05) using the
Mann-Whitney U test. This was done to assure the
validity and strengthen the rationale for the selection of
statistical methods.
For the data of the MGAT3 promoter methylation
from PBMCs, CD3+ T cells isolated from blood, and
CD3+ T cells isolated from inflamed colonic mucosa
(the Porto cohort), the Mann-Whitney U test was
applied with Bonferroni correction accounting for 15
CpG sites.
Glycan analysis
Glycans present on IgG were analyzed from serum of
over 1000 IBD (UC and CD) patients and healthy con-
trols in the Edinburgh cohort using ultra performance
liquid chromatography (UPLC) [43, 50]. In the Florence
cohort, plasma samples of 3500 IBD patients and healthy
controls was used for analysis of IgG glycopeptides by
liquid chromatography coupled to mass spectrometry
(LC-MS) [46]. The data for IgG glycosylation analysis
were used in this work for correlation analysis with pro-
moter methylation data of MGAT3 and BACH2 genes,
with matching samples from the very same patients and
healthy controls.
Isolation of IgG from blood plasma
IgG has been isolated from blood plasma by affinity
chromatography using CIM Protein G 96-well plate
(BIA Separations, Ajdovščina, Slovenia) and vacuum
manifold (Pall Corporation, Port Washington, NY, USA)
as previously described [57, 58]. In short, plasma sam-
ples (50–90 μl) were diluted with 1 × PBS, pH 7.4 in the
ratio 1:7. All samples were filtered through 0.45 and
0.2-μm AcroPrep GHP filter plates (Pall Corporation)
using vacuum manifold and immediately applied to pre-
conditioned Protein G plate. After washing of the
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Protein G plate, IgG was eluted with 0.1 mol L−1 formic
acid and immediately neutralized with ammonium bicar-
bonate to pH 7.0. Protein G plate was regenerated and
stored at 4 °C.
IgG glycosylation analysis using ultra-performance liquid
chromatography
N-glycans from isolated IgG in the Edinburgh cohort
were released with PNGase F after drying 300 μl of each
IgG elution fraction, labeled with 2-aminobenzamide
and excess of regents removed by clean-up using hydro-
philic interaction liquid chromatography solid phase
extraction (HILIC-SPE). Fluorescently labeled and puri-
fied N-glycans were separated by HILIC-UPLC using
Acquity UPLC instrument (Waters, Milford, MA, USA)
as previously described [43]. Samples were separated
into 24 peaks [57], and the amount of N-glycans in each
chromatographic peak was expressed as a percentage of
total integrated area (% area).
IgG glycosylation analysis using liquid chromatography
coupled to mass spectrometry
In the Florence cohort, Fc-specific IgG glycopeptides
were analyzed after IgG purification, overnight trypsin
digestion at 37 °C, and reverse-phase purification on
Chromabond C18 beads using vacuum manifold as
described [46, 59]. Samples were analyzed using nanoli-
quid chromatography coupled to mass spectrometry
(nanoLC-MS), on a nanoACQUITY UPLC system
(Waters, Milford Massachusetts, USA) coupled to
quadrupole-TOF-MS (Compact; Bruker Daltonics,
Bremen, Germany) equipped with a sheath-flow ESI
sprayer (capillary electrophoresis ESI-MS sprayer;
Agilent Technologies, Santa Clara, USA) as previously
described [46]. The nanoACQUITY UPLC system and
the Bruker Compact Q-TOF-MS were operated under
HyStar software version 3.2.
Data was processed as described previously [46, 60].
This resulted in the extraction of 16 IgG1, 16 IgG2/3,
and 11 IgG4 glycoforms. The tryptic Fc-glycopeptides
for IgG2 and IgG3 subclasses have identical peptide
moieties in the Caucasian population and are therefore
not distinguishable with this methodology. Annotation
of the spectra was done based on accurate mass accord-
ing to the relevant literature [40, 57].
Correlation analysis
Methylation data for the BACH2 (assay 2) and the
MGAT3 (assays 1 and 2) genes (obtained for the two
large cohorts) were filtered according to the peak quality
by rejecting peaks marked as “failed” by the pyrose-
quencing software. Average methylation across all
assayed CpG sites was calculated for each pyrosequenc-
ing assay in each cohort. Methylation results for
individual patients were matched with their correspond-
ing glycan profiles. Sizes of datasets and patient classes
obtained after including complete records (i.e., both
methylation data and glycan profiles present) are shown
in Additional file 1: Table S6. Individual glycan struc-
tures were represented as relative abundances and
batch-corrected. Percentage of structures with bisecting
N-acetylglucosamine was calculated for each cohort as a
derived trait at this point. Glycan structures identified by
each method were translated to Oxford notation, and
only the 13 structures present in both the Edinburgh
and Florence datasets were considered for correlation.
We used IgG1 data from the Florence cohort, as this
isoform was the most abundant. Three additional de-
rived traits were calculated: ratios of FA2B to FA2,
FA2BG1 to FA2G1, and FA2BG2 to FA2G2.
Pearson correlation between CpG methylation data
and 17 glycan features (13 structures and 4 derived
traits) was calculated. Significance threshold was set at
p < 0.05 with additional Bonferroni correction for
17-fold multiple testing.
Methylation of assayed CpG sites in promoters of the
BACH2 and MGAT3 genes was correlated with mea-
sured glycan structures. Pearson correlation coefficient
along with the associated p value was calculated between
average CpG methylation (for all genes/assays) and each
measured IgG glycan structure. Calculation was done on
pairwise complete observations. Only correlations with
the p value below 0.01 were considered further. Next,
correlation coefficients for all CpG assays were calcu-
lated, which was used to rank glycan structures accord-
ing to regulation by the assayed region. Glycan
structures with the strongest correlation (either positive
or negative) to CpG methylation were then used to
explain regulatory effects. All calculations and data visu-
alizations were done in R language and environment for
statistical computing (R Foundation for Statistical Com-
puting, Vienna, Austria). Visualization of correlations
was done using the R package “corrplot.”
Results
Promoter methylation of the candidate genes in whole
blood and B cells of IBD patients
In order to assess the level of methylation in CpG
islands of the five candidate genes (BACH2, MGAT3,
IKZF1, LAMB1, and IL6ST), associated with both IBD
and IgG glycosylation by GWAS, we developed sev-
eral pyrosequencing assays for each of the genes
(Fig. 1 and Additional file 2: Figure S1). We per-
formed initial screening of the pyrosequencing assays
on 60 patients. Overall cytosine methylation levels
were very low for LAMB1 (average value per group <
8%), for IL6ST (< 3.5%), and for IKZF1 (< 4%) in the
assayed portion of their promoters; therefore, we
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could not identify differential methylation. We then
excluded these genes from further analysis.
MGAT3 and BACH2 promoter methylation was ana-
lyzed in several hundred IBD patients and healthy con-
trols from two independent cohorts (Additional file 1:
Tables S1 and S2). In these genes, we analyzed methyla-
tion level at 47 CpGs covered by five pyrosequencing as-
says in the BACH2 gene: 21 CpG sites were in the
promoter region, 1 CpG site was in first exon, and 25
CpG sites were located in the first intron of the gene. A
total of 32 CpG sites, covered by five pyrosequencing
assays, was analyzed for MGAT3: 18 CpG sites were
located in the promoter region and 14 CpG sites in the
first intron (Fig. 1). Most of those CpG sites were
located within CpG islands of the both genes. We found
differential CpG methylation between IBD patients and
HC within the assay A2, located at 213–368 bp up-
stream (relative to the gene orientation) of the TSS in
the BACH2 promoter and within the assays A1 and A2,
located in the CpG island 1 of the MGAT3 gene. The
same pattern of differential methylation at these CpG
sites was observed in whole blood of patients and HC
from two large independent cohorts (Fig. 2). CpG
methylation level was generally low (up to 20%) in the
assayed portion of the BACH2 promoter; however, sig-
nificant differences between HC and CD methylation
level were recorded at CpG sites 4, 5, 6, and 8 (Fig. 2a).
For the assayed portion of the MGAT3 promoter, general
methylation level was high, with all CpG sites show-
ing a reproducibly significant difference between HC
and both CD and UC. CpG sites 2, 13, and 15
showed significant differences only for CD but not for
UC. Direction of change was different for the two
genes—differentially methylated CpG sites within the
BACH2 promoter were hypomethylated, while those
for the MGAT3 gene were hypermethylated in disease
compared to healthy individuals.
These results were confirmed on CD19+ B cells
isolated from peripheral whole blood of the independ-
ent, smaller patient sample from the Edinburgh
cohort (67 samples). The CpG sites 1–5 and 12–13 in
the MGAT3 promoter were differentially methylated
between CD and HC. Only CpG site 5 within the
assay A2 of the BACH2 gene showed change in the
methylation level between HC and CD in CD19+ B
cells (Fig. 2b). There were no differences in the
methylation level of the same CpG sites within
assayed fragments of the BACH2 and MGAT3 genes
between UC and HC.
It is worth noting that the same pattern of CpG
methylation differences was observed in PBMCs of the
IBD patients and HC from both large independent
cohorts, and most of the CpG sites within the assayed
portion of the MGAT3 promoter were also differentially
methylated in CD19+ B cells from the subset of IBD
patients from the Edinburgh cohort (Fig. 2a, b).
Fig. 1 Positions of the BACH2 and MGAT3 genes in the human genome and relative positions of the fragments analyzed for methylation level
(pyrosequencing assays) within these genes. For each pyrosequencing assay (A1–A5), the region amplified by PCR is shown. Positions of the genes on
the chromosomes are shown using chromosome models (red vertical lines). Coordinates are relative to the hg19 human genome assembly. The genes
are displayed in the direction corresponding to their reading frames. Annotations (CpG islands and pyrosequencing assays) are to scale. TSS transcription
start site
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Promoter methylation of the MGAT3 gene in CD3+ T cells
from PBMCs and inflamed colonic mucosa of UC patients
We included in our investigation biopsy samples of UC
patients from an independent cohort from the Gastro-
enterology Department of Centro Hospitalar do
Porto-Hospital de Santo António, Portugal. Given the
technical challenges in obtaining DNA and RNA from a
small number of purified cells from inflamed colonic
mucosa, a subset of patients with active and inactive
phase of UC was selected for methylation analysis from
three sources: (1) PBMCs, (2) CD3+ T cells isolated from
PBMCs, and (3) CD3+ T cells isolated from colonic
mucosa (see also Additional file 1: Table S4).
Inter-individual variation of MGAT3 methylation level
measured from PBMCs and from CD3+ T cells isolated
from PBMCs was quite large—it varied from 47 to 94%
and from 26 to 90%, respectively. Therefore, we could
not find any difference in CpG methylation level
between UC patients and HC in assayed fragments of
the MGAT3 promoter, neither in PBMCs nor in CD3+ T
cells isolated from PBMCs. However, we recorded a total
of 7 (out of 15) differentially methylated CpG sites in
CD3+ T cells isolated from colonic mucosa of UC
patients with active disease compared with HC (Fig. 3).
Overall, the methylation level of CpGs within assayed
fragments of the MGAT3 promoter was high in CD3+ T
cells from healthy colonic mucosa (between 77 and
98%). When compared to inflamed mucosa of UC
patients with active phase of the disease, the same CpG
sites were hypomethylated, with the highest difference at
the CpG position 10 (13.24%; p = 5.08 × 10−5; Fig. 3). In
inactive UC, no significant differences could be found
after Bonferroni correction for multiple testing.
It is worth noting that the methylation pattern in
CD3+ T cells isolated from inflamed colonic mucosa dif-
fered from the methylation patterns in PBMCs and for
CD3+ T cells isolated from PBMCs. The latter two were
very similar and had much lower methylation levels than
that measured for CD3+ T cells from inflamed colonic
mucosa (Fig. 3). Also, MGAT3 methylation level was
increased in UC compared with HC when measured
from PBMCs or CD3+ T cells isolated from PBMCs
(hypermethylation), while it was decreased (hypomethy-
lation) when measured from CD3+ T cells isolated from
inflamed colonic mucosa in comparison with healthy
mucosa.
Correlation between the MGAT3 and BACH2 promoter
methylation and IgG glycosylation
There were statistically significant correlations that repli-
cated across assays and cohorts between the MGAT3
promoter methylation and glycan structures FA2,
FA2G2, FA2BG2, and FA2G2S1, as well as the derived
trait of the ratio of FA2B to FA2 (Fig. 4a). All correla-
tions except with FA2 were negative. No reproducible
significant correlations could be found between BACH2
promoter methylation and the glycan structures
(Fig. 4a).
In order to infer a mechanistic pathway of the
observed correlations, we mapped them to the glycan
biosynthesis pathways (Fig. 4b). The ratio of bisecting
glycans to FA2 was taken as an indicator of MGAT3
(GnT-III) activity. This interpretation allowed us to infer
lower GnT-III enzymatic activity when the promoter of
the MGAT3 gene was methylated. Increase in MGAT3
promoter methylation correlated with a decrease in cer-
tain galactosylated and sialylated structures (Fig. 4b). In
addition to the decreased levels of bisecting GlcNAc on
non-galactosylated glycans (B/FA2), the most significant
effect of the MGAT3 promoter methylation on IgG gly-
come composition was a decrease of IgG galactosylation.
Discussion
Results from this study strongly indicate that the
MGAT3 and BACH2 genes play an important role in
IBD pathogenesis and suggest a possible disease pathway
mediated by the pro-inflammatory properties of IgG
antibodies acquired by alterations in Fc glycosylation.
Our recent study, performed on a large cohort of over
1000 IBD patients, reported a significant difference in
IgG glycome composition in both UC and CD compared
to healthy controls [43, 46]. We found a decrease in
quantity of galacosylated glycans in both CD and UC, as
well as a decrease in sialylated glycans and an increase
of bisecting GlcNAc on digalactosylated glycan struc-
tures on IgG in CD. Indeed, alternative N-glycosylation
of an IgG molecule influences its function—pro-inflam-
matory and anti-inflammatory activity depends on the
(See figure on previous page.)
Fig. 2 Box plot of CpG methylation in peripheral whole blood for the BACH2 and MGAT3 genes in the Edinburgh and Florence cohorts and in B
cells from a subset of patients from Edinburgh cohort. Groups were compared using the Mann-Whitney U test with significance threshold of p= 0.05,
corrected for multiple testing using the Bonferroni method. a Methylation levels were generally low in the assayed portion of the BACH2 gene promoter,
with significant differences between HC and CD methylation at CpG sites 4, 5, 6, and 8 (replicated in both cohorts). For the MGAT3 gene, general
methylation level was high, with all CpG sites showing a reproducibly significant difference between HC and both CD and UC, except for CpG sites 2, 13,
and 15 for which reproducible significant differences were found only between HC and CD. b In B cells, isolated from PBMCs of a subset of the patients
from the Edinburg cohort, differential methylation was found at the CpG position 5 of the BACH2 gene (assay 2) between HC and CD, while for the MGAT3
gene, differentially methylated were CpG sites 1–5, 12, and 13 between HC and CD. CD Crohn’s disease, UC ulcerative colitis, HC healthy controls
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glycans added on the Cy2 domain of its Fc region [29].
These glycans are of a biantennary complex type with or
without bisecting GlcNAc, core fucose, galactose, and
sialic acid residues [61]. Recently, this was confirmed in
a large multi-centric study of IgG glycome in IBD [46].
Therefore, glycan changes observed on IgG in peripheral
blood of UC and CD patients are obviously associated
with increased inflammatory potential of IgG, suggesting
functional relevance of IgG glycosylation for IBD.
Here, we propose a possible mechanism underlying
the aberrant IgG glycosylation pattern observed in IBD
[43, 46]. Out of five candidate genes analyzed in this
work, the MGAT3, a glycosyltransferase which partici-
pates in synthesis of IgG glycans, and the BACH2, a
transcription factor and a master regulator of a network
of genes relevant for B cell integrity [62, 63], showed dif-
ferential methylation in peripheral blood of both CD
and UC patients when compared to healthy individuals.
Even though we identified changes in methylation level
for both UC and CD compared to HC, the differences
were more pronounced for CD. This is concordant with
other studies that explored either whole genome methy-
lation or promoter methylation of candidate genes in
IBD [11]. The extent of the change in IgG glycome com-
position was also consistently higher in CD than UC
compared to HC [43, 46].
The protein encoded by the MGAT3 gene (N-acetyl-
glucosaminyltransferase III, GnT-III) is responsible for
significant functional alteration of glycans on the Fc
region of an IgG antibody. The GnT-III adds N-acetyl-
glucosamine (GlcNAc) on β1,4-linked mannose in the
three-mannose core of N-glycans, producing bisecting
GlcNAc structures. In the same CD patients, who
showed changed MGAT3 promoter methylation level in
peripheral blood cells, a significant increase in the per-
centage of bisecting GlcNAc on glycans of circulating
IgG antibodies was recorded, too. The association of the
MGAT3 with both IgG N-glycosylation [49] and Crohn’s
disease [4, 5] suggests that N-glycans with bisecting
GlcNAc could be involved in CD pathogenesis through
functional effect on IgG antibody.
Correlations between BACH2 and MGAT3 promoter
methylation and glycan structures have given further
insight into the changes of IgG glycosylation pattern me-
diated by those two genes (Fig. 4b). The MGAT3
a
b
c
Fig. 3 Box plot of CpG methylation level in the MGAT3 gene promoter
(assays A1 and A2) analyzed from PBMCs (a), CD3+ T cells isolated from
PBMCs (b), and CD3+ T cells isolated from inflamed colonic mucosa (c)
from the independent cohort of Porto. Changes between UC patients
with active disease and HC were statistically significant only in CD3+ T
cells isolated from inflamed colonic mucosa at CpG positions 3 and 7–12
(p< 0.05 after Bonferroni correction for 15 hypotheses). PBMC peripheral
blood mononuclear cells, UC ulcerative colitis, HC healthy controls
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promoter methylation probably led to decreased GnT-III
enzymatic activity, as revealed by negative correlation
between methylation and total bisecting glycans to FA2
ratio. Namely, GnT-III adds a bisecting GlcNAc to FA2.
A further proof is the positive correlation between the
MGAT3 promoter methylation and FA2, since it is not
surprising that substrate accumulates when enzyme ac-
tivity is decreased. More complex effects were observed
on galactosylation and sialylation. The negative correl-
ation between MGAT3 methylation and galactosylation
of both, glycans with (FA2BG2) and without bisecting
GlcNAc (FA2G2), suggests that the effect of increased
galactosylation is not caused only by steric effects of
bisecting GlcNAc, but also through some indirect effects
of MGAT3 expression on galactosyltransferase activity. It
seems as though galactosylation and sialylation are
co-regulated with the addition of a bisecting GlcNAc
catalyzed by GnT-III. Furthermore, Dekkers and
co-workers recently reported that transfection of cells
with MGAT3 causes an increase of IgG galactosyla-
tion [64].
Much weaker correlation was observed between BACH2
methylation and IgG glycosylation. This was expected since
BACH2 is not a glycosyltransferase and thus is not directly
involved in glycan biosynthetic pathways. However, weak
positive correlations with A2G2, FA2G2, and FA2G2S1
structures, which involve galactosylation and sialylation,
were observed, as well as weak negative correlation with
fucosylated bianntenary structure FA2. This is interesting
because GWA studies associated BACH2 with IgG galacto-
sylation [49] as well as with various immune and inflam-
matory diseases including IBD [4, 5, 65–67] in which IgG
acquires pro-inflammatory properties through decrease in
galactosylation, sialylation, and fucosylation [43, 46]. Since
BACH2 is orchestrating a gene regulatory network in B
cells [62], we believe that some glyco-genes are also regu-
lated by this transcription factor. Indeed, our in silico
analysis identified several glyco-genes, mostly galactosyl-
transferases (including B4GALT1 and B4GALT2), to pos-
sess putative AP-1 and NFE2 binding sites for BACH2
transcription factor [63], suggesting that these galactosyl-
transferases could be controlled by BACH2
(Additional file 1: Tables S7 and S8). Our present efforts
are focused on functional studies with hope to reveal a
more complete view of the BACH2 role in IgG
glycosylation.
Since DNA methylation pattern is tissue-specific, our
goal was to ascertain if CpG methylation from blood
could be a proxy for CpG methylation of the same
candidate gene in the tissue where the inflammation is
taking place. In fact, IBD is an immune-mediated dis-
order in which T cells are actively implicated in develop-
ment of gut-mucosa inflammation [68]. Previous
evidence has suggested that N-glycosylation of intestinal
T cells is associated with UC pathogenesis and disease
severity [50, 69]. Therefore, we analyzed MGAT3 pro-
moter methylation in CD3+ T cells isolated from PBMCs
and from intestinal mucosa of UC patients with active
and inactive form of the disease and compared with
MGAT3 promoter methylation from PBMCs of the same
patients from the Porto cohort. We found 7 out of 15
differentially methylated CpG sites in CD3+ T cells
isolated from colonic mucosa of UC patients with active
form of the disease compared to CD3+ T cells from mu-
cosa of healthy individuals. On the other hand, there
were no differences in MGAT3 promoter methylation
between patients with either active or inactive form of
UC and healthy controls neither in PBMCs nor in CD3+
T cells isolated from PBMCs. This could be due to high
dispersion in the methylation level when measured from
PBMCs (47–94%) and CD3+ T cells isolated from
PBMCs (26–90%), probably due to small sample size
and dispersion in age. Namely, cell composition changes
across age in whole blood, and it can explain dispersion
of CpG methylation level observed in our sample [70].
Considering much smaller dispersion in values of methy-
lation level (65–97%) measured from CD3+ T cells from
lamina propria, the differences could be used as a signa-
ture for inflammation.
Conclusions
Taken together, our results suggest that the aberrant
methylation observed in the MGAT3 gene in CD3+ T
cells from intestinal mucosa of UC patients, B cells from
(See figure on previous page.)
Fig. 4 Correlations between CpG methylation in the BACH2 and MGAT3 gene promoters and glycan structures measured from the same individuals of
the Edinburgh and Florence cohorts, mapped to the glycan biosynthesis pathways. a Correlation coefficients between average CpG methylation in the
assayed gene promoter fragments and glycan structure percentages are shown as blue (positive) or red (negative correlation) circles with their size and
shade proportional to the correlation coefficient. Correlations without statistical significance (p> 0.05 after Bonferroni correction for multiple testing) are
crossed. Columns represent 13 individual glycan structures and four derived traits (beige box). EDI Edinburgh cohort, FLO Florence cohort, Bisecting,
percentage of all structures with bisecting N-acetylglucosamine, B/FA2 ratio of FA2B to FA2 structures, B/FA2G1 ratio of FA2BG1 to FA2G1 structures, B/
FA2G2 ratio of FA2BG2 to FA2G2 structures. b Glycan biosynthesis pathways with the glycan structures, labels, and the enzymes mapped to correlation
results for the MGAT3 gene. Light blue rectangles indicate positive, while light red rectangles indicate negative correlation between the glycan structures
or traits and CpG methylation levels. Only correlations replicated across assays and/or cohorts are shown. The red rectangle around the MGAT3 enzyme
reflects the negative correlation between CpG methylation and the derived trait B/FA2, which effectively measures enzyme activity at this step. MGAT3
N-acetilglucosaminyltransferase III (GnT-III), FUT8 fucosyltransferase 8, GalT1 galactosyltranserase 1, ST6GalT1 Beta-galactoside alpha-2,6-sialyltransferase 1
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peripheral blood, and the whole peripheral blood in UC
and CD patients is a possible mechanism underlying in-
flammation due to a change in the immune system—ei-
ther through the change of glycans on Fc region of IgGs
or by modulating the glycosylation profile of glycopro-
teins on intestinal T cells. Others [24] have shown that
some of their candidate genes changed promoter methy-
lation level in whole biopsies, while some of the genes
showed changes only in some cell types of the heteroge-
neous cell population from the epithelial and
non-epithelial cells, pointing out the importance of cell
separation from mucosal biopsies. Interestingly, one of
the genes that showed differential methylation in the
non-epithelial fraction, representing immune and stro-
mal cells, was FUT7, the fucosyltransferase involved in
sialyl Lewis X synthesis, a ligand in selectin-mediated
adhesion of leukocytes to activated endothelium. Fur-
thermore, Dias and collaborators proposed a molecular
mechanism in IBD involving another glyco-gene, the
MGAT5 (GnT-V), responsible for branching of N-gly-
cans. They showed decreased expression of branched
N-glycans on T cell receptor (TCR) of lamina propria
associated with disease severity in patients with active
UC [50]. Dysregulation of N-glycan branching on TCR
contributes to a decreased threshold of T cell activation
leading to a hyper-immune response which is a feature
of UC patients. Taken together, our results and those of
others suggest an important role of aberrant protein
glycosylation (partly through epigenetic mechanisms) in
IBD through dysregulation of the immune system. Also,
in IBD diagnosis and treatment, it is important to find a
non-invasive, specific, and clinically useful biomarkers in
order to identify high-risk patients. Using MGAT3
hypermethylation together with the glycan traits as
markers from peripheral blood of IBD patients seems
promising in the disease identification.
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